Industry News
Biotechnology Industry News
While the average earnout…
While the average earnout potential per biopharma deal has declined over the last six years, the mean upfront value has been on the rise since 2017.
Sparrow Pharmaceuticals is looking…
Sparrow Pharmaceuticals is looking to send its potential diabetes treatment soaring through clinical trials with the help of a $95 million series B, the company announced in a Sept. 24 release.
Harmony Biosciences’ $60 million…
Harmony Biosciences’ $60 million bet on a once-failed Fragile X candidate has gone off the rails. Two years after picking up ZYN002 despite a midphase flop, the biotech has reported that a registrational trial of
UniQure has set its sights on…
UniQure has set its sights on submitting its Huntington’s disease gene therapy for approval next year after the asset was shown to slow progression of the neurodegenerative condition by 75% in a phase 1/2 trial
When it comes to Cyclerion’s…
When it comes to Cyclerion’s colorful backstory, the only consistency has been its inconsistency.
Sanofi is bestowing $625 million…
Sanofi is bestowing $625 million on its investment arm Sanofi Ventures, seeking to take advantage of a biotech landscape that is light on capital yet still heavy on scientific innovation.
Rome Therapeutics is on the ropes,…
Rome Therapeutics is on the ropes, with the Boston-based preclinical biotech planning layoffs for the end of the month, evaluating strategic options for its assets and ditching its physical headquarters to go entirely virtual, a
The New York Stock Exchange helped…
The New York Stock Exchange helped ring in this year’s Fierce 15 by honoring the winners on the trading floor Monday morning.
Seres Therapeutics is laying off a…
Seres Therapeutics is laying off a quarter of its workforce as the microbiome biopharma conserves resources to take its bloodstream infection preventive treatment into phase 2.
Bristol Myers Squibb has ended its…
Bristol Myers Squibb has ended its R&D losing streak with a hit on one of the dual primary endpoints in a phase 3 multiple myeloma trial. But, with the study continuing to evaluate the other
Roche’s head of metabolic…
Roche’s head of metabolic product development said the company is firing “on full cylinders” to get a phase 3 trial of its GLP-1/GIP drug launched next year.
Merck & Co. has doubled down…
Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate on small molecule candidates against two targets.
MapLight Therapeutics has…
MapLight Therapeutics has illuminated a path toward an initial public offering, filing with the Securities and Exchange Commission to be listed on the Nasdaq under the ticker symbol "MPLT."
Angelini Pharma has worked out a…
Angelini Pharma has worked out a $550 million-plus biobucks deal to get its hands on a Korean biotech’s preclinical neuro asset.
Ionis Pharmaceuticals is eyeing a…
Ionis Pharmaceuticals is eyeing a new rare disease approval after its antisense oligonucleotide zilganersen successfully improved mobility in patients with the neurological condition Alexander disease.
Pfizer has thrown money at its…
Pfizer has thrown money at its obesity R&D problem. Having seen its internal assets flounder, the Big Pharma has struck a deal to buy Metsera for an initial $4.9 billion to secure a pipeline of
Roche has set its sights on…
Roche has set its sights on becoming a “top three” obesity company, according to the pharma’s long-awaited strategy for cracking the weight loss market.
Roche has reported a phase 3 win…
Roche has reported a phase 3 win for its oral selective estrogen receptor degrader, bouncing back from an earlier setback to deliver data that could support filings for approval in breast cancer.
Genfit has stopped development of…
Genfit has stopped development of VS-01 in acute-on-chronic liver failure after a patient suffered a serious adverse event in a phase 2 trial.
Sanofi’s long and winding path…
Sanofi’s long and winding path to get its investigational multiple sclerosis drug over the regulatory finish line has taken another turn with the FDA's move to delay its approval decision on the candidate by three